{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:58Z","timestamp":1786985098206,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bprclinrheum.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.berh.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T12:22:43Z","timestamp":1473769363000},"page":"239-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Catastrophic antiphospholipid syndrome: The current management approach"],"prefix":"10.1016","volume":"30","author":[{"given":"Ignasi","family":"Rodriguez-Pint\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2016.07.004_bib1","first-page":"508","article-title":"The catastrophic antiphospholipid syndrome","volume":"19","author":"Asherson","year":"1992","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2016.07.004_bib2","first-page":"195","article-title":"The catastrophic antiphospholipid syndrome\u2013asherson's syndrome","volume":"154","author":"Piette","year":"2003","journal-title":"Ann M\u00e9d Interne"},{"key":"10.1016\/j.berh.2016.07.004_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00005792-199805000-00005","article-title":"Catastrophic antiphospholipid syndrome. clinical and laboratory features of 50 patients","volume":"77","author":"Asherson","year":"1998","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2016.07.004_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00005792-200111000-00002","article-title":"Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients","volume":"80","author":"Asherson","year":"2001","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2016.07.004_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.autrev.2006.06.007","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors","volume":"6","author":"Bucciarelli","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.07.004_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.07.004_bib7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2016.07.004_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/ard.2004.025759","article-title":"Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome","volume":"64","author":"Cervera","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.07.004_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0961203310395051","article-title":"Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria aps manifestations (i): catastrophic APS, APS nephropathy and heart valve lesions","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2016.07.004_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.autrev.2010.08.005","article-title":"Catastrophic antiphospholipid syndrome: updated diagnostic algorithms","volume":"10","author":"Erkan","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.07.004_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/0961203309106812","article-title":"European working party on systemic lupus erythematosus and European Forum on antiphospholipid antibodies: two networks promoting European research on autoimmunity","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2016.07.004_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/ard.2006.067033","article-title":"Is there a microangiopathic antiphospholipid syndrome?","volume":"66","author":"Asherson","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.07.004_bib13","first-page":"1793","article-title":"Microangiopathic antiphospholipid-associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes","volume":"34","author":"Asherson","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2016.07.004_bib14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.autrev.2007.11.009","article-title":"Microvascular and microangiopathic antiphospholipid-associated syndromes (\u201cmaps\u201d): semantic or antisemantic?","volume":"7","author":"Asherson","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.07.004_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/096120339200100402","article-title":"Multiorgan thrombotic disorders in systemic lupus erythematosus: a common link?","volume":"1","author":"Asherson","year":"1992","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2016.07.004_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201ccaps registry\u201d","volume":"32","author":"Cervera","year":"2009","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.berh.2016.07.004_bib17","first-page":"923","article-title":"Catastrophic antiphospholipid syndrome and sepsis. a common link?","volume":"34","author":"Espinosa","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2016.07.004_bib18","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"Bucciarelli","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.07.004_bib19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/ard.2004.026377","article-title":"Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients","volume":"64","author":"Asherson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.07.004_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/ard.2003.007245","article-title":"Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies","volume":"63","author":"Espinosa","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.07.004_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/15733971113099990003","article-title":"Catastrophic antiphospholipid syndrome - 20 years later","volume":"9","author":"Rodr\u00edguez-Pint\u00f3","year":"2013","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.berh.2016.07.004_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-014-0482-z","article-title":"Catastrophic APS in the context of other thrombotic microangiopathies","volume":"17","author":"Rodr\u00edguez-Pint\u00f3","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2016.07.004_bib23","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14th international Congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome","volume":"13","author":"Cervera","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.07.004_bib24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1055\/s-0028-1082274","article-title":"Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors","volume":"34","author":"Espinosa","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.berh.2016.07.004_bib25","first-page":"346","article-title":"The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus","volume":"34","author":"Bayraktar","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2016.07.004_bib26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.07.004_bib27","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.berh.2016.07.004_bib28","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.07.004_bib29","first-page":"585","article-title":"Catastrophic antiphospholipid syndrome: an orchestra with several musicians","volume":"16","author":"Rodr\u00edguez-Pint\u00f3","year":"2014","journal-title":"IMAJ"},{"key":"10.1016\/j.berh.2016.07.004_bib30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cll.2013.01.003","article-title":"Catastrophic antiphospholipid syndrome. Diagnosis and management in pregnancy","volume":"33","author":"G\u00f3mez-Puerta","year":"2013","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.berh.2016.07.004_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/eci.12.48","article-title":"8th International Congress on Autoimmunity: new perspectives for refractory catastrophic antiphospholipid syndrome","volume":"8","author":"Cervera","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.berh.2016.07.004_bib32","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/0961203314540764","article-title":"Catastrophic antiphospholipid syndrome: task force report summary","volume":"23","author":"Cervera","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2016.07.004_bib33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/0885066606287041","article-title":"Care medicine catastrophic antiphospholipid syndrome","volume":"21","author":"Vora","year":"2006","journal-title":"J\u00a0Intensive Care Med"},{"key":"10.1016\/j.berh.2016.07.004_bib34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/0961203309361353","article-title":"Catastrophic antiphospholipid syndrome (CAPS): update from the \u2018CAPS Registry\u2019","volume":"19","author":"Cervera","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2016.07.004_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/sarh.2001.27660","article-title":"Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases","volume":"31","author":"Amital","year":"2001","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.07.004_bib36","first-page":"192","article-title":"N2010 adult-onset Still's disease complicated by hemophagocytic syndrome and catastrophic antiphospholipid syndrome resulting in four limb amputation","volume":"15","author":"Sacks","year":"2013","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.berh.2016.07.004_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2014.09.002","article-title":"Bridging therapy in antiphospholipid syndrome and antiphospholipid antibodies carriers: case series and review of the literature","volume":"14","author":"Raso","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.07.004_bib38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2010.10.018","article-title":"Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group","volume":"124","author":"Kitchens","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2016.07.004_bib39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0002-9343(98)00061-8","article-title":"Thrombotic storm: when thrombosis begets thrombosis","volume":"104","author":"Kitchens","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2016.07.004_bib40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1586\/ehm.12.56","article-title":"Clinical causes and treatment of the thrombotic storm","volume":"5","author":"Ortel","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.berh.2016.07.004_bib41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0032-1304718","article-title":"Update on the catastrophic antiphospholipid syndrome and the \u2018CAPS Registry\u2019","volume":"38","author":"Cervera","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.berh.2016.07.004_bib42","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/0961203310395052","article-title":"Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (II): thrombocytopenia and skin manifestations","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2016.07.004_bib43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.autrev.2006.06.013","article-title":"Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome","volume":"6","author":"Erkan","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2016.07.004_bib44","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/CCM.0b013e3181c98d21","article-title":"Inflammation and coagulation","volume":"38","author":"Levi","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.berh.2016.07.004_bib45","first-page":"455","article-title":"Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in\u00a0vitro","volume":"101","author":"Franklin","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.berh.2016.07.004_bib46","first-page":"2070","article-title":"Corticosteroids for septic shock","volume":"358","author":"Manoach","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2016.07.004_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semreu.2013.02.002","article-title":"Recambio plasm\u00e1tico en las enfermedades autoinmunes sist\u00e9micas","volume":"14","author":"Pons-Estel","year":"2013","journal-title":"Semin Fund Esp Reumatol"},{"key":"10.1016\/j.berh.2016.07.004_bib48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2016.07.004_bib49","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nrrheum.2015.88","article-title":"Current treatment of antiphospholipid syndrome: lights and shadows","volume":"11","author":"Espinosa","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2016.07.004_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic Apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for Apheresis: the Sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.berh.2016.07.004_bib51","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2016.07.004_bib52","first-page":"409","article-title":"Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin","volume":"30","author":"Sciascia","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2016.07.004_bib53","first-page":"877","article-title":"Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy","volume":"31","author":"Tenti","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2016.07.004_bib54","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00262-001-0237-3","article-title":"Th2\/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model","volume":"50","author":"Matar","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.berh.2016.07.004_bib55","series-title":"Antiphospholipid antibody syndrome SE \u2013 20","first-page":"249","article-title":"The catastrophic antiphospholipid syndrome catastrophic antiphospholipid syndrome","author":"Rodr\u00edguez-Pint\u00f3","year":"2015"},{"key":"10.1016\/j.berh.2016.07.004_bib56","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.07.004_bib57","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Khamashta M a. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2016.07.004_bib58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","article-title":"Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients","volume":"50","author":"Calich","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.berh.2016.07.004_bib59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2016.07.004_bib60","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A\u00a0pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.07.004_bib61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0961203307085251","article-title":"Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature","volume":"17","author":"Erre","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2016.07.004_bib62","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.berh.2016.07.004_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/tjh.2015.0197","article-title":"The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome","volume":"5","author":"Erkan","year":"2016","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.berh.2016.07.004_bib64","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transpl"},{"key":"10.1016\/j.berh.2016.07.004_bib65","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMe1406870","article-title":"The mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Eikelboom","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2016.07.004_bib66","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.berh.2016.07.004_bib67","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.berh.2016.07.004_bib68","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.atherosclerosis.2014.01.040","article-title":"mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques","volume":"233","author":"Martinet","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.berh.2016.07.004_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"371","key":"10.1016\/j.berh.2016.07.004_bib70","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"16","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2016.07.004_bib71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1164\/rccm.201011-1897CI","article-title":"Systemic steroids in severe sepsis and septic shock","volume":"185","author":"Patel","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.berh.2016.07.004_bib72","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1196\/annals.1422.057","article-title":"In\u00a0vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies","volume":"1108","author":"Montiel-Manzano","year":"2007","journal-title":"Ann N Y Acad Sci"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T09:51:22Z","timestamp":1536400282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694216300407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1521694216300407"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2016.07.004","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Catastrophic antiphospholipid syndrome: The current management approach","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}